Entral Feeding in Acute Severe Pancreatitis
Lykilorð
Útdráttur
Lýsing
- The study was conducted on monitoring of four pillar for 13 days (data collected one day before feeding and every three days for 12 days). the first pillar comparing the effect of the two enteral feeding methods on the clinical condition of the acute severe pancreatitis and this monitored clinically and laboratory by fixed parameters, clinically, by abdominal pain which assessed by visual analogue scale (VAS). and laboratory, by both markers of severity of pancreatic acini destruction which assessed by serum amylase, lipase and Markers of severity of interstitial pancreatic tissue destruction which assessed by the level of Lactate Dehydrogenase level (LDH), Aspartate aminotransferase (AST), C-reactive protein, prostacyclin and interleukin 8. The second pillar include effect of the two enteral feeding methods on the patient's tolerance and these monitored in our study by both post-feeding vomiting and post feeding attacks of osmotic diarrhea and also abdominal pain. Third pillar include effect of the two enteral feeding methods on the patient's general condition and these monitored by follows the APACHE II Score, hemodynamics of the patients in both groups (Mean arterial blood pressure and pulse) and arterial oxygen saturation (Spo2). Fourth pillar include effect of the two enteral feeding methods on achieving satisfactory nutrition parameters of the patients and both albumin level, radium blood sugar and electrolytes (sodium and potassium level) used as indicator for this.
- All parameters observed one day before starting feeding and every 3 days for 12 days (duration of the study).
Dagsetningar
| Síðast staðfest: | 04/30/2020 |
| Fyrst lagt fram: | 05/20/2020 |
| Áætluð skráning lögð fram: | 05/26/2020 |
| Fyrst sent: | 05/27/2020 |
| Síðasta uppfærsla lögð fram: | 05/26/2020 |
| Síðasta uppfærsla sett upp: | 05/27/2020 |
| Raunverulegur upphafsdagur náms: | 06/09/2018 |
| Áætlaður aðallokunardagur: | 04/01/2020 |
| Áætlaður dagsetningu rannsóknar: | 04/09/2020 |
Ástand eða sjúkdómur
Íhlutun / meðferð
Device: Group A
Device: Group B
Drug: (erythromycin 250 mg IV bolus)
Stig
Armhópar
| Armur | Íhlutun / meðferð |
|---|---|
| Group A Group A received nasogastric feeding (NG), insure through ngt pump | Device: Group A • The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube |
| Group B receive feeding throughThe nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.
Patients were placed in right lateral position | Device: Group B The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.
Patients were placed in right lateral position |
Hæfniskröfur
| Aldur hæfur til náms | 18 Years Til 18 Years |
| Kyn sem eru hæf til náms | All |
| Sýnatökuaðferð | Probability Sample |
| Tekur við heilbrigðum sjálfboðaliðum | Nei |
| Viðmið | Inclusion Criteria: - acute pancreatitis Exclusion Criteria: - systemic disease as hypertension or diabetes |
Útkoma
Aðal niðurstöður ráðstafanir
1. effect of different methods of feeding in the clinical condition of the acute severe pancreatitis [13 days]
